Raleigh biotech developing therapeutics for migraine and other headache disorders. Lead program SLTE-1009 is a subcutaneous anti-PACAP monoclonal antibody in-licensed from DartsBio Pharmaceuticals, targeting a pathway distinct from CGRP.
At a glance
- HQ: Raleigh
- Sector: Biotech
- Stage: Series A
- Total raised: $130M
- Last round: Series A
This is the free preview.
The full profile is for members: founders, funding history, investor connections, and recent signals. Accounts are free; I review every request, usually within 48 hours.